

Addendum: Sequencing of *BRCA1/2*-alterations using NGS-based technology: annotation as a challenge

Silvana Ebner¹, Ria Winkelmann¹, Saskia Martin¹, Jens Köllermann¹, Peter J. Wild^{1,2} and Melanie Demes^{1,2}

¹Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany

²Wildlab, University Hospital MVZ GmbH, Frankfurt am Main, Germany

Published: August 30, 2023

Copyright: © 2023 Ebner et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: No external funding was obtained.

Original article: Oncotarget. 2022; 13:464–475. <https://doi.org/10.18632/oncotarget.28213>